TLPH Quote, Financials, Valuation and Earnings

GB Sciences, Inc. has a net margin of -443600% compared to Talphera, Inc.'s net margin of --. Talphera, Inc.'s return on equity of -127.04% beat GB Sciences, Inc.'s return on equity of --.

Talphera, Inc. has a consensus price target of $3.25, signalling upside risk potential of 256.52%. On the other hand GB Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Talphera, Inc. has higher upside potential than GB Sciences, Inc., analysts believe Talphera, Inc. is more attractive than GB Sciences, Inc..

Talphera, Inc. has a beta of 0.475, which suggesting that the stock is 52.538% less volatile than S&P 500. In comparison GB Sciences, Inc. has a beta of 11.460, suggesting its more volatile than the S&P 500 by 1045.961%.

Talphera, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GB Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Talphera, Inc. pays -- of its earnings as a dividend. GB Sciences, Inc. pays out -- of its earnings as a dividend.

Talphera, Inc. quarterly revenues are $1K, which are larger than GB Sciences, Inc. quarterly revenues of --. Talphera, Inc.'s net income of -$4.4M is lower than GB Sciences, Inc.'s net income of -$190.5K. Notably, Talphera, Inc.'s price-to-earnings ratio is -- while GB Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Talphera, Inc. is 1,045.82x versus 1.26x for GB Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Iovance Biotherapeutics, Inc. has a net margin of -443600% compared to Talphera, Inc.'s net margin of -82.92%. Talphera, Inc.'s return on equity of -127.04% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.64%.

Talphera, Inc. has a consensus price target of $3.25, signalling upside risk potential of 256.52%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.80 which suggests that it could grow by 127.98%. Given that Talphera, Inc. has higher upside potential than Iovance Biotherapeutics, Inc., analysts believe Talphera, Inc. is more attractive than Iovance Biotherapeutics, Inc..

Talphera, Inc. has a beta of 0.475, which suggesting that the stock is 52.538% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.690, suggesting its less volatile than the S&P 500 by 30.977%.

Talphera, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Talphera, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Talphera, Inc. quarterly revenues are $1K, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $86.7M. Talphera, Inc.'s net income of -$4.4M is higher than Iovance Biotherapeutics, Inc.'s net income of -$71.9M. Notably, Talphera, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Talphera, Inc. is 1,045.82x versus 5.23x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protokinetix, Inc. has a net margin of -443600% compared to Talphera, Inc.'s net margin of --. Talphera, Inc.'s return on equity of -127.04% beat Protokinetix, Inc.'s return on equity of -111.59%.

Talphera, Inc. has a consensus price target of $3.25, signalling upside risk potential of 256.52%. On the other hand Protokinetix, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Talphera, Inc. has higher upside potential than Protokinetix, Inc., analysts believe Talphera, Inc. is more attractive than Protokinetix, Inc..

Talphera, Inc. has a beta of 0.475, which suggesting that the stock is 52.538% less volatile than S&P 500. In comparison Protokinetix, Inc. has a beta of 0.654, suggesting its less volatile than the S&P 500 by 34.642%.

Talphera, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protokinetix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Talphera, Inc. pays -- of its earnings as a dividend. Protokinetix, Inc. pays out -- of its earnings as a dividend.

Talphera, Inc. quarterly revenues are $1K, which are larger than Protokinetix, Inc. quarterly revenues of --. Talphera, Inc.'s net income of -$4.4M is lower than Protokinetix, Inc.'s net income of -$84.9K. Notably, Talphera, Inc.'s price-to-earnings ratio is -- while Protokinetix, Inc.'s PE ratio is 23.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Talphera, Inc. is 1,045.82x versus -- for Protokinetix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -443600% compared to Talphera, Inc.'s net margin of -316.61%. Talphera, Inc.'s return on equity of -127.04% beat Plus Therapeutics, Inc.'s return on equity of --.

Talphera, Inc. has a consensus price target of $3.25, signalling upside risk potential of 256.52%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1716.98%. Given that Plus Therapeutics, Inc. has higher upside potential than Talphera, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Talphera, Inc..

Talphera, Inc. has a beta of 0.475, which suggesting that the stock is 52.538% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.788, suggesting its less volatile than the S&P 500 by 21.173%.

Talphera, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Talphera, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Talphera, Inc. quarterly revenues are $1K, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Talphera, Inc.'s net income of -$4.4M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Talphera, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Talphera, Inc. is 1,045.82x versus 4.85x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.